Attack on 76-year-old worker at North Texas hospital sparks calls for stronger protections for health care staff
The victim, a 76-year-old woman and longtime employee at the hospital, was working as a direct observer or sitter during the incident, sources told CBS News Texas. She was assigned to sit with a 30-year-old patient to watch over him Thursday overnight.
It's not clear how long she was there, but at some point, the patient allegedly became violent, sources said.
According to an affidavit filed by Baylor Scott & White's police force, in an unprovoked attack, the man began to "repeatedly punch the victim," hitting her more than a dozen times in the face and "rendering [her] unconscious."
She was left with "severe pain, bruising, swelling, and bleeding" on the left side of her face, authorities said.
According to a GoFundMe account set up by her colleagues, she "will now require surgery" and "faces a long road to physical, mental, and emotional healing."
Baylor Scott & White Health released the following statement:
"First and foremost, we are caring for our team member, supporting her physically, emotionally, and financially as she recovers. And we are equally focused on supporting our frontline colleagues with enhanced resources, including additional security on campus."
The hospital said it is also reviewing its procedures in response.
The unidentified man has now been charged with six counts of felony assault, and the incident has sparked a larger conversation about the safety of health care workers.
One nurse wrote on social media: "this happens every day...verbal and physical abuse... we all have stories."
Others have called for increased security.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Here's how millions of people could lose health insurance if Trump's tax bill becomes law
WASHINGTON (AP) — Roughly 11.8 million adults and children will be at risk for losing health insurance if Republicans' domestic policy package becomes a law. The losses won't come all at once. The GOP's ' One Big, Beautiful Bill Act ' makes changes that will whittle away at enrollment through federal health care programs like Medicaid and Obamacare over a decade in order to wrest nearly $1 trillion from Medicaid, the Affordable Care Act, and the Children's Health Insurance Program. The bill is likely to reverse years of escalating health insurance rates in the U.S., gains that have also been marked by record spending on federally-funded health care coverage. Roughly 78 million adults and children are enrolled in Medicaid's programs while 24 million people are enrolled in the ACA's marketplaces. Medicaid is a joint federal-state venture that is administered by the states. The program goes by different names in some states, like Medi-Cal in California, BadgerCare in Wisconsin, or MassHealth in Massachusetts. A look at some of the ways in which people may lose health care coverage under the GOP's plan: Medicaid or Obamacare enrollee? Your income and eligibility will be checked closely and more often. Under the GOP's plan, states will need to verify a person's income to check Medicaid eligibility every six months. People who are homeless or transient may miss notices from the government to fill out paperwork more frequently, said Martha Santana-Chin, the CEO of L.A. Care Health Plan, which provides Medicaid for millions of Los Angelenos. They'll lose their coverage if they don't respond. 'The life experience of these individuals is not necessarily one that allows them the luxury of having to work through onerous paperwork,' Santana-Chin said. When Texas increased income eligibility checks between 2014 and 2019, for example, thousands of kids lost coverage in the state. Critics faulted the frequent checks, too, for the state having the highest rate of uninsured children in the nation at the time. States will also be required to check enrollees' addresses and death records more frequently. People enrolled in the ACA's marketplace coverage will also be subject to more scrutiny over their reported income and face penalties if they end up earning more than they expected when signing up for the coverage. They'll have to wait for the government to verify their information, too, before getting coverage. It will be a sharp contrast from employer-based coverage, where people are re-enrolled every year unless they opt out. Is your child enrolled in coverage? States will be allowed to delay kids from enrolling in the Children's Health Insurance Program in some cases. They will be allowed to temporarily block parents from enrolling their children if they are behind on paying the premiums for the coverage. Those premiums for kids' coverage can run as much as $100 a month in some states, according to health policy research firm KFF. States will also be able to introduce a waiting period for kids who are being transitioned from private health insurance plans to Medicaid. The Biden administration prohibited states from locking out parents from enrolling their kids in coverage over missed payments or a waiting period when transitioning from private health insurance. Are you an immigrant? Getting coverage may get harder. The bill narrows the definition of who qualifies for lower Obamacare, restricting access for thousands of refugees and asylum seekers who come to the U.S. every year. States that offer Medicaid coverage to cover immigrants who may not be here legally will also receive less money from the federal government. Several states allow immigrants to enroll in Medicaid, paid for only using state tax dollars. But the bill threatens that coverage by lowering the rate the federal government pays for all legal residents from 90% to 80%. That will lead some states to drop their program for immigrants entirely rather than lose federal funding. Already, California has announced a freeze on any new enrollment for the state funded Medi-Cal for all immigrants. Illinois, meanwhile, halted its program this month. Able-bodied? You'll have to work, volunteer or go to school. Most coverage losses are expected to come from the GOP's proposed work requirement. People aged 19 through 64 will be required to work, volunteer or go to school for 80 hours per month in order to qualify for Medicaid under the new law. They'll be exempt if they're disabled, pregnant or parent a child who is 14 or younger. Ultimately, some people will decide they don't want to work and don't need the coverage, said Michael F. Cannon, director of health policy studies at the libertarian think tank Cato Institute. 'It can encourage people who don't value Medicaid coverage not to sign up for it,' Cannon said. 'And that saves the government money.' Most Medicaid enrollees already work, attend school, have a disability or are caregivers, which should exempt them from the requirement. Only about 8% of enrollees report not working or being unable to find work. In some cases, people will lose coverage even if they're working. They will fall victim to bureaucratic errors, overlooked forms, or trouble getting all of the documents — like proof of employment and tax forms — together to prove to the government that they're working. Verifying work will be especially difficult for people who don't have access to the internet, a computer or phones. That's how some people lost coverage in Arkansas, which tried to enact work requirements in 2018. Roughly 18,000 people were pushed off Medicaid within seven months. A federal judge later blocked the requirement. Enrolled in both Medicare and Medicaid? It will be harder to apply Millions of people qualify for both Medicare and Medicaid, often because of a disability. The GOP bill will roll back requirements of the ways the Biden administration streamlined enrollment for those people, including a rule that required states to automatically enroll people into coverage if they qualify for supplemental income because of a disability. 'By rescinding these rules and no longer requiring states to make some of these simplifications, it's likely that some people will lose coverage because they get caught up in these paperwork burdens,' said Jennifer Tolbert, director of state health policy at KFF.
Yahoo
35 minutes ago
- Yahoo
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
Follow-Up to June 5, 2025, Announcement Demonstrates Validated Vaccine Candidate with Strong Translational Potential AUSTIN, Texas, June 24, 2025--(BUSINESS WIRE)--ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery. This new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable. "This is a major step forward," said Dr. Jennifer Bath, CEO of ImmunoPrecise. "Our AI technology not only found a new target for a universal dengue vaccine, but we've now shown it's safe and can trigger the right immune response. With this validation, we're excited to move ahead and advance this candidate toward the next stages of vaccine development." Following the recent discovery of a unique "Achilles' heel" shared by all four types of dengue virus, ImmunoPrecise has confirmed—using its patented HYFT technology and LENSai Immunogenicity Screener—that the selected target not only remains conserved but also triggers a strong and specific immune response. This breakthrough may pave the way for a safer, more universal dengue vaccine. The new target was discovered using the Company's proprietary LENSai platform. "Our ability to move from computational discovery to AI-guided immunogenicity validation is unique to our methodology and drug development," commented Dr. Jennifer Bath, ImmunoPrecise CEO. "Further, it ensures that our candidates are both theoretically promising and primed for real-world immune protection, a critical requirement for any viable vaccine candidate." For decades, dengue has been one of the most challenging viruses for vaccine developers, largely because the virus comes in four different forms—and beating one doesn't guarantee protection from the others. Many vaccines fail because they trigger the immune system to attack the wrong parts of the virus, or worse, make infections more severe. What makes this development so important is that ImmunoPrecise's target has now been shown—based on in silico immune profiling—to likely engage key components of the immune system, including both B cells and T cells, in a manner that appears safe and highly specific. ImmunoPrecise's latest AI-driven testing shows that their selected target—a small, stable piece of the virus—can activate the body's defenses in a very precise way, without the risks of traditional, broader approaches. A Methodology That Changes the Game—Far Beyond Dengue What sets ImmunoPrecise apart is not only the discovery of a promising dengue vaccine target, but the methodology itself. With LENSai powered by HYFT technology, IPA brings unprecedented clarity to the earliest stages of discovery—well before traditional disease modeling or animal studies even begin. By revealing deep relationships between sequence, structure, and function at the outset, this platform provides rapid, explainable insights that inform every downstream decision, from epitope selection to vaccine design. The findings for dengue showcase the platform's versatility. Because HYFT technology systematically maps biological meaning across the entire biosphere, this methodology is readily transferable—equipping IPA to tackle a wide spectrum of infectious diseases, from HIV and influenza to emerging pathogens and oncology targets. With this approach, ImmunoPrecise isn't just keeping pace with the field; it's setting a new standard for how next-generation therapeutics are discovered and validated. ImmunoPrecise's patented HYFT technology successfully identified a critical and discontiguous target site (epitope) that remains unchanged across all four types of dengue virus (DENV-1 through DENV-4). This target site is essential for how the virus infects cells and is believed to be key for establishing an enduring and efficacious universal dengue vaccine. This HYFT-guided workflow achieves this by analyzing protein building blocks that may be far apart in the virus's genetic sequence but come together when the protein folds into its final 3D shape. This advanced mapping process combines genetic similarity analysis with 3D structural modeling and functional annotation to identify the most promising vaccine targets. Key Technical Findings Complete Immune Response TestingComputer-based immune response screening used advanced prediction tools to evaluate how both antibody-producing cells (B cells) and infection-fighting cells (T cells) would respond to the vaccine target. The target site showed strong predicted binding to multiple human immune system markers (HLA class I and II types). This suggests that people from diverse backgrounds and genetic makeups could mount a strong immune response to the vaccine—something essential for global deployment. Safety Verification Against Human ProteinsUsing ImmunoPrecise's proprietary retrieve-and-relate technology at the core of HYFT™ (Van Hyfte et al., 2023, bioRxiv), the vaccine target was thoroughly compared against all known human and mouse proteins. This comprehensive safety check goes beyond standard comparison methods—HYFT systematically searches for not only genetic similarities but also structural and functional matches across species, ensuring the vaccine target is unique to the virus and not found in human biology. This is critical in vaccine development, where off-target effects can lead to dangerous autoimmune reactions. No problematic similarities were found, significantly reducing the risk that the vaccine would accidentally attack the body's own healthy cells. Structural Stability AnalysisAdvanced computer modeling and molecular simulation studies have confirmed that the vaccine target maintains its proper shape, remains accessible to immune cells, and remains prominently displayed on the surface of the dengue virus. Stability testing demonstrated that the target remains robust under normal physiological conditions. Balanced Immune Response ProfileImportantly, the moderate predicted immune response strength (compared to typical vaccine 'hotspots') may explain why this target was overlooked in previous laboratory studies that focused on more obvious, highly immunogenic sites. This balanced profile suggests the vaccine could trigger a highly specific immune response while potentially reducing the risk of dangerous immune overreactions or antibody-dependent enhancement (ADE)—a serious complication that can worsen dengue infection. Looking Ahead This release is the second in a series of disclosures aimed at showcasing the power of ImmunoPrecise's end-to-end AI-native platform. The June 5th announcement introduced a promising target; today's release provides the crucial next step: a rigorous validation of that target's safety and immunological relevance. This validation significantly strengthens the translational potential of the candidate, which is currently being prepared for further preclinical evaluation. These findings come at an important time, as global agencies continue to seek safer and more effective dengue vaccines. IPA is actively engaging with key stakeholders to explore the path forward, including potential collaboration, development, and funding partnerships. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," or similar expressions, or by statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. These statements include, but are not limited to, statements regarding the anticipated benefits, scalability, and broader application of the LENSai™ and HYFT® platforms to dengue vaccine development; the advancement, regulatory acceptance, and future clinical potential of AI-native approaches for dengue and other infectious diseases; and the Company's ability to achieve and maintain scientific, regulatory, and commercial progress in its dengue program. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, the pace of scientific and technological developments, changes in regulatory requirements or acceptance of AI designed vaccines, competition and market dynamics, intellectual property protection, risks related to preclinical or clinical validation of dengue vaccine candidates, integration and operational challenges, and changes in global economic or business conditions. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. View source version on Contacts Investor Relations Contact Louie TomaManaging Director, CORE IRinvestors@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
CNN
an hour ago
- CNN
U.S. House takes up Trump Agenda bill
The House takes up the revised Senate version of President Trump's sweeping domestic agenda bill, which passed the Senate on Tuesday by the slimmest of margins. CNN Political Analyst and Historian Leah Wright Rigueur says if the bill becomes law, people will remember Donald Trump as the President who increased the national debt and took away people's healthcare.
